Hypermarcas (OTCMKTS:HYPMY) Short Interest Update

Hypermarcas (OTCMKTS:HYPMY) was the recipient of a significant decline in short interest in the month of July. As of July 31st, there was short interest totaling 3,256 shares, a decline of 43.9% from the July 15th total of 5,807 shares. Approximately 0.0% of the company’s shares are short sold. Based on an average daily volume of 19,962 shares, the days-to-cover ratio is currently 0.2 days.

Wall Street Analysts Forecast Growth

Several equities research analysts have weighed in on the stock. Zacks Research upgraded shares of Hypermarcas to a “hold” rating in a report on Wednesday, April 29th. Jefferies Financial Group upgraded shares of Hypermarcas to a “strong-buy” rating in a research report on Monday, July 20th. One analyst has rated the stock with a Strong Buy rating and one has given a Hold rating to the company’s stock. Based on data from MarketBeat, the company currently has a consensus rating of “Buy”.

Hypermarcas Stock Down 2.7%

Shares of HYPMY traded down $0.12 on Monday, hitting $4.08. The company’s stock had a trading volume of 699 shares, compared to its average volume of 22,021. The firm’s fifty day moving average price is $4.09 and its 200-day moving average price is $4.34. Hypermarcas has a fifty-two week low of $3.71 and a fifty-two week high of $5.50. The firm has a market capitalization of $2.87 billion, a price-to-earnings ratio of 8.15 and a beta of 0.70.

Hypermarcas (OTCMKTS:HYPMY) last announced its earnings results on Thursday, August 6th. The company reported $0.14 EPS for the quarter, topping the consensus estimate of $0.13 by $0.01. Hypermarcas had a net margin of 19.77% and a return on equity of 14.63%. As a group, equities analysts predict that Hypermarcas will post 0.53 earnings per share for the current fiscal year.

About Hypermarcas

Hypermarcas SA is a Brazil-based consumer health and pharmaceutical company whose shares trade over the counter in the United States under the symbol HYPMY. Founded in the early 2000s and headquartered in Rio de Janeiro, the company operates as a holding group for a broad portfolio of branded products in the healthcare and personal care sectors.

Through its various subsidiaries, Hypermarcas develops, manufactures and markets prescription and over-the-counter medications, alongside personal care, baby care, home care and nutritional supplement products.